This is a new avenue in genetic research focused on iron-sulfur cluster pathway disruptors. These disruptors, including N’-(1-(2-hydroxyphenyl)-propylidene)-benzohydrazides and N’-(1-(2-hydroxyphenyl)-ethylidene)-benzohydrazides, offer potential applications in altering the iron-sulfur cluster maturation process. Their development signifies a departure from previously explored compounds, particularly those with LSD1 inhibitory activity, thus introducing cleaner compounds for targeted disruption. Ongoing proof of concept testing is slated for completion by year-end. The IP offers a promising path for therapeutic exploration, and the potential applications of these disruptors span various human pathologies, including cancer and infectious diseases.